AASraw is with synthesis and production ability from gram to mass order of Lapatinib (CAS 231277-92-2), under CGMP regulation and trackable quality control system.
Lapatinib powder is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug Capecitabine. Lapatinib is human epidermal growth factor receptor type 2 (HER2/ERBB2) and epidermal growth factor receptor (HER1/EGFR/ERBB1) tyrosine kinases inhibitor. It binds to the intracellular phosphorylation domain to prevent receptor autophosphorylation upon ligand binding.
AASraw is with synthesis and production ability from gram to mass order of Lapatinib powder (231277-92-2), under CGMP regulation and trackable quality control system.
lapatinib powder is a cancer medicine that interferes with the growth and spread of cancercells in the body. lapatinib powder is used to treat a certain type of hormone-related breast cancer that has progressed or spread after treatment with other cancer medicines. In postmenopausal women, lapatinib powder is given in combination with a hormonal medicine called letrozole (Femara). In others, lapatinib powder is given together with a cancer medicine called capecitabine (Xeloda).
Lapatinib powder video I.Lapatinib powder basic Characters: Name: Lapatinib powder CAS: 231277-92-2 Molecular Formula: C29H26ClFN4O4S Molecular Weight: 581.05 Melt Point: 136-140°C Storage Temp: Refrigerator Color: White or off white Crystalline powder 1.Tykerb powder basic Characters. Name Tykerb Cas 231277-92-2 Molecular Formula C29H26CIFN4O4S Molecular Weight 581.05 Color White or off white Crystalline […]